Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2006

View Archived Issues

Lipid Sciences files IDE for Plasma Delipidation System-2

Private placement funds to support phase II Reolysin development

Zydus Cadila files IND for antiinflammatory compound ZYI-1

Samaritan initiates new phase IIb for SP-01A in HIV

Positive results from synDNA hepatitis B study

InSite Vision completes debt refinancing to support AzaSite development and filing

Recordati signs agreement with Osmotica for modified-release lercanidipine

sNDA submission for Seroquel in bipolar depression

Cerus files IND for phase I study of CRS-100

New designer antibacterial agents from Rib-X Pharmaceuticals

MBX-037 demonstrates antibacterial potential of DNA polymerase IIIC inhibitors

New agents with activity against HIV reported in patent literature

New agents and strategies for respiratory disorders

Cervical cancer vaccine induces greater response in younger women

Inhaled aztreonam reduces P. aeruginosa in cystic fibrosis patients

NDA submission for telbivudine in chronic hepatitis B

U.S. launch for Increlex

Symadex studied in metastatic breast cancer

KRX-0401 studied in new phase II trial for multiple myeloma

Selective targeting of the immunoproteasome for hematologic malignancies

Nonapprovable letter for Cesamet labeling changes

AZD-2479 for dyslipidemia begins phase I study

Studies reveal antibiotic activity of CSA-13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...